| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 418.94M | 272.03M | 84.73M | 1.76B | 487.62M | 178.40M |
| Gross Profit | 310.71M | 91.24M | -38.14M | 1.44B | 352.50M | 168.14M |
| EBITDA | 69.20M | -28.54M | 660.91M | 2.74B | -261.99M | -173.42M |
| Net Income | -44.53M | -67.33M | 670.09M | 1.44B | -594.74M | -563.82M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 3.75B | 3.79B | 3.39B | 5.05B | 5.66B |
| Cash, Cash Equivalents and Short-Term Investments | 6.16M | 6.16M | 75.02M | 84.33M | 93.33M | 39.34M |
| Total Debt | 0.00 | 232.51M | 432.30M | 1.19B | 3.73B | 3.55B |
| Total Liabilities | -2.20B | 1.55B | 1.50B | 2.31B | 6.85B | 6.50B |
| Stockholders Equity | 2.20B | 2.22B | 2.30B | 1.48B | -456.88M | 112.44M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 179.22M | -21.88M | 3.27B | -220.89M | 61.83M |
| Operating Cash Flow | 0.00 | 188.62M | 373.00K | 3.27B | -130.80M | 62.08M |
| Investing Cash Flow | 0.00 | 12.95M | 63.92M | -1.23B | -78.52M | 73.22M |
| Financing Cash Flow | 0.00 | -213.50M | -78.45M | -2.03B | 173.32M | -99.39M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ₹8.65B | 11.84 | ― | ― | -7.04% | -53.33% | |
68 Neutral | ₹13.98B | 27.61 | ― | 0.50% | 9.24% | 3.74% | |
55 Neutral | $13.29B | 17.42 | 10.03% | 0.93% | 7.13% | -12.93% | |
52 Neutral | ₹7.33B | 9.79 | ― | ― | 297.44% | -106.98% | |
46 Neutral | ₹6.46B | ― | ― | ― | 43.60% | 32.19% |
PVP Ventures Limited has announced its compliance with Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. The company has submitted a certificate from KFin Technologies Limited, confirming that the details of securities dematerialized or rematerialized for the quarter ending September 30, 2025, have been provided to all relevant stock exchanges. This announcement underscores PVP Ventures Limited’s commitment to regulatory compliance, which may positively influence investor confidence and uphold its reputation in the market.
PVP Ventures Limited has announced a change in its secretarial auditors, appointing M/s. ARS & Associates Company Secretaries LLP for a five-year term. This appointment, approved at the company’s 34th Annual General Meeting, is in accordance with the amended SEBI regulations, and is expected to enhance the company’s compliance and governance framework, potentially impacting its operational efficiency and stakeholder confidence.
PVP Ventures Limited has been asked by the Exchange to clarify discrepancies in their financial results submitted in XBRL format for the quarter ending June 30, 2025, as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company’s response is currently awaited, which may impact its compliance status and investor confidence.
PVP Ventures Limited has acquired a 41.23% stake in 7 Med India Pvt. Ltd. and Epitome Group of Hospitals, with plans to increase its stake to 76% over time. This acquisition aligns with PVP’s strategy to create a global healthcare services platform focused on illness, wellness, and care. 7Med, a leading provider in India’s renal care space, operates a profitable network of dialysis centers and hospitals, and with PVP’s investment, aims to expand its services and infrastructure in Tier 2 and Tier 3 cities. This move is expected to enhance PVP’s industry positioning and create sustainable value for stakeholders.